AstraZeneca Soliris recommended for nod in EU by CHMP for children, adolescents with refractory generalised myasthenia gravis

gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.

John F. Brandsema, MD, Children’s Hospital of Philadelphia and primary investigator in the Phase III trial of paediatric patients, said, “Onset of gMG in paediatric patients is extremely rare and complex to manage. As the disease progresses, patients may become nonresponsive to standard treatments, leaving them at risk for serious complications. The Phase III clinical trial results in patients aged 12 to 17 years with refractory gMG show the efficacy of C5 inhibition in substantially reducing disease severity and symptoms, potentially transforming how this debilitating disease is managed in certain paediatric patients.”

Marc Dunoyer, Chief Executive Officer, Alexion, said, “gMG can impact patients’ ability to walk, talk, breathe and participate in routine activities, and with no existing targeted therapies for children and adolescents with this condition, families have long been hopeful for a treatment. If approved, Soliris would be the first targeted treatment for paediatric patients living with refractory gMG in Europe, offering the possibility of improved outcomes and quality of life.”

The efficacy and safety of Soliris in paediatric patients aged six years and older is consistent with the established profile of Soliris in clinical trials involving adults with refractory gMG. In the Phase III clinical trial of paediatric patients, the majority of reported adverse events were considered mild or moderate. 

Soliris was first approved in the EU in 2017 for the treatment of certain adults with gMG and is also approved for certain adults with gMG in the US, China and Japan. Regulatory submissions for Soliris for the treatment of paediatric patients with gMG are currently ongoing or planned with multiple health authorities.